The recent publication of three case reports of endometrial pathology including leiomyoma related to the consumption of soy food (Chandrareddy et al. 2008) has been challenged for apparent inconsistencies, among other the reported intake of 40 g of isoflavones/day (corresponding to 400 litres of soy milk!), a gross overestimation of the isoflavone content in supplements as compared with soy food, and the lack of corresponding adverse event observations in studies with the systematic assessment of safety parameters relevant for breast and endometrial health (Messina 2008).
Overall, these case reports are very poorly documented and assessed, and quite obviously the causality was only attributed to soy because of the current debate of hypothetical risks of “phyto-estrogens”.
Safety 